胆汁淤积性肝病药物治疗研究进展

摘要/Abstract

摘要： 胆汁淤积性肝病是以胆汁在肝内蓄积导致肝胆组织损伤和功能障碍为特征的疾病。核受体(NR)是调控包括肝脂质代谢、葡萄糖代谢、能量消耗和胆汁酸(BA)体内平衡的关键转录因子,而这些过程的失调是胆汁淤积以及脂肪性肝病的重要致病机制。既往基于NR已经开发了靶向的高亲和力治疗配体,包括法尼醇-X受体(FXR)和过氧化物酶体增殖物激活受体(PPARs)的激动剂。除此之外,成纤维细胞生长因子19(FXR-19)的类似物,以及肝细胞和肠细胞的BA摄取抑制剂也对胆汁淤积性肝病有良好的治疗潜力。因此,本文就近年来胆汁淤积性肝病的靶向药物研究做一综述。

关键词: 胆汁淤积性肝病, 胆汁酸, 核受体, 肠肝循环, 治疗

葛启超, 陆伦根. 胆汁淤积性肝病药物治疗研究进展[J]. 肝脏, 2023, 28(11): 1261-1263.

参考文献

[1] Banales JM, Huebert RC, Karlsen T, et al. Cholangiocyte pathobiology[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(5): 269-281.
[2] Dawson PA, Haywood J, Craddock AL, et al. Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice[J]. J Biol Chem, 2003, 278(36): 33920-33927.
[3] Van Wessel DBE, Thompson RJ, Gonzales E, et al. Impact of Genotype, Serum Bile Acids, and Surgical Biliary Diversion on Native Liver Survival in FIC1 Deficiency[J]. Hepatology, 2021, 74(2): 892-906.
[4] Nevens F, Trauner M, Manns MP. Primary biliary cholangitis as a roadmap for the development of novel treatments for cholestatic liver diseases?[J]. J Hepatol, 2023, 78(2): 430-441.
[5] Tian S, Chen S, Pan C, et al. FXR: structures, biology, and drug development for NASH and fibrosis diseases[J]. Acta Pharmacol Sin, 2022, 43(5): 1120-1132.
[6] Beuers U. New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond[J]. J Hepatol, 2015, 62(1 Suppl):S25-37.
[7] Halilbasic E, Claudel T, Trauner M. Bile acid transporters and regulatory nuclear receptors in the liver and beyond[J]. J Hepatol, 2013, 58(1): 155-168.
[8] Trauner M, Fuchs CD. Novel therapeutic targets for cholestatic and fatty liver disease[J]. Gut, 2022, 71(1): 194-209.
[9] John BV, Schwartz K, Levy C, et al. Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis[J]. Hepatol Commun, 2021, 5(8)5(8):1426-1436.
[10] Fiorucci S,Distrutti E. Bile acids and their receptors[M]. Cham, Switzerland: Springer, 2019.
[11] Trauner M, Gulamhusein A, Hameed B, et al. The Nonsteroidal farnesoid X receptor agonist Cilofexor (GS‐9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis[J]. Hepatology, 2019, 70(3): 788-801.
[12] Gadaleta RM, Scialpi N, Peres C, et al. Suppression of Hepatic Bile Acid Synthesis by a non-tumorigenic FGF19 analogue Protects Mice from Fibrosis and Hepatocarcinogenesis[J]. Sci Rep, 2018, 8(1): 17210.
[13] Harrison SA, Rinella ME, Abdelmalek MF, et al. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet, 2018, 391(10126): 1174-1185.
[14] Ghonem NS, Assis DN, Boyer JL. On fibrates and cholestasis: A review[J]. 2015.
[15] Corpechot C, Chazouillères O, Rousseau A, et al. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis[J]. N Engl J Med, 2018, 378(23): 2171-2181.
[16] Jones D, Boudes PF, Swain MG, et al. Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study[J]. Lancet Gastroenterol Hepatol, 2017, 2(10): 716-726.
[17] Thompson RJ, Arnell H, Artan R, et al. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(9): 830-842.
[18] Gonzales E, Hardikar W, Stormon M, et al. Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study[J]. Lancet, 2021, 398(10311): 1581-1592.
[19] Miethke AG, Zhang W, Simmons J, et al. Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice[J]. Hepatology (Baltimore, Md.), 2016, 63(2): 512-523.
[20] Baghdasaryan A, Fuchs CD, Österreicher CH, et al. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis[J]. J Hepatol, 2016, 64(3): 674-681.
[21] Hegade VS, Kendrick SFW, Dobbins RL, et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study[J]. Lancet (London, England), 2017, 389(10074): 1114-1123.
[22] Mayo MJ, Pockros PJ, Jones D, et al. A randomized, controlled, phase 2 study of Maralixibat in the treatment of itching associated with primary biliary cholangitis[J]. Hepatol Commun, 2019, 3(3): 365-381.
[23] Levy C, Kendrick S, Bowlus CL, et al. GLIMMER: A randomized phase 2b dose-ranging trial of Linerixibat in primary biliary cholangitis patients with pruritus[J]. Clin Gastroenterol Hepatol, 2023, 21(7): 1902-1912.e13.
[24] Caballero-Camino FJ, Rodrigues PM, Wångsell F, et al. A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multiorgan activity and shows translational relevance to humans[J]. Hepatology, 2023, 78(3): 709-726.
[25] Sauter G, Berr F, Beuers U, et al. Serum concentrations of 7alpha-hydroxy-4-cholesten-3-one reflect bile acid synthesis in humans[J]. Hepatology, 1996, 24(1): 123-126.